Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (111-120 of 164) with videos related to

Pageof 17
Sort By:
Journal of Hematology & Oncology|July 3, 2026
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armGuillaume Cartron, Isabelle Chaillol, Roch Houot, et al.
American Journal of Hematology|May 17, 2021
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia OrganizationCharline Moulin, Francis Guillemin, Thomas Remen, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Cancer|April 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world studyArthur Coste, Nanthara Sritharan, Anne Lok, et al.
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Leukemia|October 7, 2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA studyRoch Houot, Guillaume Cartron, Fontanet Bijou, et al.
Pageof 17

Showing results (111-120 of 164) with videos related to

Sort By:
Pageof 17
Journal of Hematology & Oncology|July 3, 2026
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armGuillaume Cartron, Isabelle Chaillol, Roch Houot, et al.
American Journal of Hematology|May 17, 2021
Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia OrganizationCharline Moulin, Francis Guillemin, Thomas Remen, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Cancer|April 15, 2026
Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world studyArthur Coste, Nanthara Sritharan, Anne Lok, et al.
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II TrialLuc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Blood|February 4, 2021
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphomaFranck Morschhauser, Pierre Feugier, Ian W Flinn, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Leukemia|October 7, 2018
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA studyRoch Houot, Guillaume Cartron, Fontanet Bijou, et al.
Pageof 17